Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Wheeler

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Medical Virology|January 1, 1983
Unrelatedness of factor VIII-derived non-A/non-B hepatitis and hepatitis B virusH A Fields, M Berninger, N Nath, et al.
The Journal of Infectious Diseases|October 13, 2001
Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titerD R Brown, J T Bryan, J M Schroeder, et al.
Journal of Clinical Microbiology|October 17, 1998
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategiesC L Peyton, M Schiffman, A T Lörincz, et al.
Cancer Research|September 10, 1998
Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variantsL F Xi, C W Critchlow, C M Wheeler, et al.
Epidemiology and Infection|June 12, 2015
Prevalent high-risk HPV infection and vaginal microbiota in Nigerian womenE O Dareng, B Ma, A O Famooto, et al.
The Journal of Infectious Diseases|October 27, 2001
Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa RicaS S Wang, C M Wheeler, A Hildesheim, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Medical Virology|January 1, 1983
Unrelatedness of factor VIII-derived non-A/non-B hepatitis and hepatitis B virusH A Fields, M Berninger, N Nath, et al.
The Journal of Infectious Diseases|October 13, 2001
Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titerD R Brown, J T Bryan, J M Schroeder, et al.
Journal of Clinical Microbiology|October 17, 1998
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategiesC L Peyton, M Schiffman, A T Lörincz, et al.
Cancer Research|September 10, 1998
Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variantsL F Xi, C W Critchlow, C M Wheeler, et al.
Epidemiology and Infection|June 12, 2015
Prevalent high-risk HPV infection and vaginal microbiota in Nigerian womenE O Dareng, B Ma, A O Famooto, et al.
The Journal of Infectious Diseases|October 27, 2001
Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa RicaS S Wang, C M Wheeler, A Hildesheim, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 6